Happi Staff02.18.20
There's a new topical athritis gel heading to store shelves. The Food and Drug Administration (FDA) has approved GlaxoSmithKline’s Voltaren Arthritis Pain (diclofenac sodium topical gel, 1% (NSAID)- arthritis pain reliever) as an over-the-counter (OTC) product for the temporary relief of arthritis pain in the hand, wrist, elbow, foot, ankle or knee in adults (18 years and older).
With the FDA's approval, Voltaren Arthritis Pain becomes the first and only prescription strength, nonsteroidal anti-inflammatory (NSAID) topical gel for arthritis pain available OTC in the US; the gel, which GlaxoSmithKline owns the rights to, had been only available with a prescription in the US.
"For the millions of people around the world living with arthritis, joint pain and stiffness are daily realities,” said Franck Riot, head of R&D, GSK Consumer Healthcare. “At GSK, we are committed to improving the quality of life of these people and today's approval is progress towards this, providing consumers in the US with increased access to an effective, proven arthritis pain relief option. Voltaren is currently the number 1 OTC topical pain relief brand globally, and we look forward to expanding its availability in the US."
The active ingredient in Voltaren Arthritis Pain, diclofenac sodium, is an effective medicine that is clinically proven to relieve joint pain due to arthritis. Voltaren Arthritis Pain penetrates through the skin at the application site to deliver arthritis pain relief. Voltaren Arthritis Pain offers consumers who suffer from OA an alternative option to oral analgesics. It targets pain directly at the site and the amount of diclofenac sodium that is systemically absorbed from Voltaren Arthritis Pain is on average 6% of the systemic exposure from an oral form of diclofenac sodium. GSK anticipates Voltaren Arthritis Pain will be available on US shelves in Spring 2020.
With the FDA's approval, Voltaren Arthritis Pain becomes the first and only prescription strength, nonsteroidal anti-inflammatory (NSAID) topical gel for arthritis pain available OTC in the US; the gel, which GlaxoSmithKline owns the rights to, had been only available with a prescription in the US.
"For the millions of people around the world living with arthritis, joint pain and stiffness are daily realities,” said Franck Riot, head of R&D, GSK Consumer Healthcare. “At GSK, we are committed to improving the quality of life of these people and today's approval is progress towards this, providing consumers in the US with increased access to an effective, proven arthritis pain relief option. Voltaren is currently the number 1 OTC topical pain relief brand globally, and we look forward to expanding its availability in the US."
The active ingredient in Voltaren Arthritis Pain, diclofenac sodium, is an effective medicine that is clinically proven to relieve joint pain due to arthritis. Voltaren Arthritis Pain penetrates through the skin at the application site to deliver arthritis pain relief. Voltaren Arthritis Pain offers consumers who suffer from OA an alternative option to oral analgesics. It targets pain directly at the site and the amount of diclofenac sodium that is systemically absorbed from Voltaren Arthritis Pain is on average 6% of the systemic exposure from an oral form of diclofenac sodium. GSK anticipates Voltaren Arthritis Pain will be available on US shelves in Spring 2020.